Santander

• An Open Label Study to Assess the Effect of Patient Use and Robustness on Tiotropium Bromide Spray 2.5μg, Soft Mist Inhaler device Pending
  2025-522412-16-00 3 Chronic obstructive pulmonary disease
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso … Pending
  2025-522586-30-00 5 Psoriatic Arthritis
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Carcinoma, Transitional Cell
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy … Pending
  2025-523010-89-00 3 Pulmonary arterial hypertension
• A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0 … Pending
  2025-523058-16-00 4 Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhib
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5 Relapsed or Refractory Multiple Myeloma
• Symbiotic-GU-06-A Study to Learn About the Study Medicine PF-08634404 Alone or In Combination With Enfortumab Vedotin in Adult Participants … Pending
  2025-523523-21-00 9 Locally Advanced or Metastatic Urothelial Cancer
• A study to investigate dabogratinib (TYRA-300) in participants with Low Grade Upper Tract Urothelial Carcinoma Pending
  2025-523539-20-00 4 Low Grade Upper Tract Urothelial Carcinoma
• A Phase 1 Study of AIR-001 in Adults with AATD. Pending
  2025-523558-14-00 1 Alpha-1 Antitrypsin Deficiency
• SAVE trial Pending
  2025-523709-13-00 5 Acute ischemic stroke
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• A study to test single and multiple doses of MER511 given to adults with Graves’ disease Pending
  2025-523823-23-00 1 Graves’ disease
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Pending
  2025-524056-63-00 1 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m … Pending
  2025-524408-30-01 5 Metastatic hormone-sensitive prostate cancer
• PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR … Pending
  2025-524613-89-00 9 HER2 positive advanced breast cancer
• Immunosuppressant Discontinuation in Elderly patients with ulcerative colitis And long-term remission Pending
  2025-524675-23-00 6 Ulcerative Colitis
• A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s … Pending
  2025-524843-11-00 4 Non-Small Cell Lung Cancer
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-21 Uncontrolled Moderate to Severe Eosinophilic Asthma
• AURA-IPF: A Randomized Phase 2 Study to evaluate the safety and efficacy of AP02 (nintedanib solution) in IPF Recruiting
  2025-523431-19-00 4 2026-05-20 Idiopathic Pulmonary Fibrosis (IPF)
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos … Recruiting
  2024-511496-14-00 5 2026-05-14 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting
  2025-522896-27-00 4 2026-05-11 Asthma

Showing 25–48 of 596 trials